# QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

> **NCT04864782** · PHASE2,PHASE3 · TERMINATED · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 46 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** QL1604
- **DRUG:** Paclitaxel injection
- **DRUG:** Cisplatin/Carboplatin

## Key facts

- **NCT ID:** NCT04864782
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-23
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-11-01
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Phase 2 completed, phase 3 sponsor decided to terminate
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864782, "QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04864782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*